Leadership
-
Jonathan Violin has deep experience aligning clinical and scientific evidence with strategies to efficiently finance discovery and development of novel therapeutics. He was the co-founder of privately-held Viridian Therapeutics and led the firm’s operations prior to its acquisition by miRagen Therapeutics (now Viridian Therapeutics, Inc., Nasdaq: VRDN). He previously served as founding CEO of two virtual drug discovery companies, Quellis Biosciences and Dianthus Therapeutics. Prior to that, Jonathan co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. Jonathan holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.
-
Dr. Katz is an internationally recognized neuro-ophthalmologist with deep experience in clinical development of therapeutics to treat eye diseases. He came to Viridian Therapeutics from BridgeBio Pharma, Inc. where he developed therapeutics to treat orphan eye diseases as President and CMO of Retinagenix Therapeutics and Fortify Therapeutics. Prior to BridgeBio, Dr. Katz served as CMO at GenSight Biologics, S.A. in Paris, where he oversaw early- and late-stage clinical programs. He held the Francis DeJur Chair of Ophthalmology at the Montefiore Medical Center and Albert Einstein College of Medicine in New York, serving as Professor of Ophthalmology, Neurology and Neurosurgery as well as Executive Director of the Office of Clinical Trials. He previously served as CEO of Danube Pharmaceuticals, CMO of Fovea Pharmaceuticals and VP for Medical Affairs and Strategy at Eyetech. Dr. Katz received an M.D. from Case-Western Reserve University School of Medicine, an M.B.A. from the University of Rochester’s Simon School of Business, and an A.B. from Colgate University.
-
Vahe has expertise in ensuring that drug discovery platforms, screening strategies, and testing cascades match the pathophysiological characteristics of therapeutic targets and deliver new molecular entities that address patients’ needs. He was the co-founder privately-held Viridian Therapeutics and led the firm’s scientific efforts prior to its acquisition by miRagen Therapeutics (now Viridian Therapeutics, Inc., Nasdaq: VRDN). He previously served as founding CSO of two virtual drug discovery companies, Quellis Biosciences and Dianthus Therapeutics. Prior to that, Vahe served for 10 years at AstraZeneca focused on antibody therapeutics and immuno-oncology as Director, Search and Evaluation, Global Product and Portfolio Strategy; other roles. Previously, Vahe spent eight years at Pfizer where he helped establish the company’s biologics strategy across therapeutic areas and led discovery efforts for four INDs and a Phase 3 program. Vahe started his career in academic research, serving as Director of the hybridoma and DNA sequencing core facilities at the University of Pennsylvania. Vahe holds a Ph.D. in Biophysics from SUNY Buffalo and a M.S. and B.S. in Physics from the American University of Beirut.
-
Tomas Kiselak is currently managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak served as a managing director at RA Capital Management LLC, based in Boston. In addition to his responsibilities at Fairmount, Mr. Kiselak serves as a strategic advisor to Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Kiselak also serves on the board of directors of Zenas BioPharma. He received his BA in Neuroscience and Economics from Amherst College.
-
Peter Harwin is currently managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as strategic advisor to Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. and serves as Chairman of the Board of Cogent Biosciences, Inc. Mr. Harwin served on the board of directors of Viridian Therapeutics, Inc. prior to its acquisition by miRagen Therapeutics (renamed Viridian Therapeutics). He received his Bachelor of Business Administration from Emory University.
-
Arlene M. Morris has been a director of Viridian Therapeutics since January 2018. She has extensive experience in the pharmaceutical and biotechnology industries serving in numerous management and board roles.
Ms. Morris currently serves as Chief Executive Officer at Willow Advisors, LLC, a consultancy advising biotech companies on financing, strategy and business development. From April 2012 until May 2015 she was Chief Executive Officer of Syndax Pharmaceuticals, Inc., an oncology company focused on the development and commercialization of therapies for treatment-resistant cancers. She also served as a member of the Syndax Pharmaceuticals board of directors from June 2011 until May 2015.
From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm; Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company; Scios Inc., a publicly traded biopharmaceutical company; and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viveve, Inc., a public medical device company; Palatin Technologies, a public biotechnology company. She was recently a director of Biodel Inc., a public specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016; and Dimension Therapeutics, a public gene therapy company, until it was acquired by Ultragenyx in 2017. She is currently a director emeritus for the Foundation for Research and Development at the Medical University of South Carolina and as a trustee of Carlow University. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
-
Jennifer Moses is currently the Chief Financial Officer of G1 Therapeutics, Inc., a commercial-stage oncology company. In her role as Chief Financial Officer, she is responsible for the financial operations of the company, including SEC reporting, financing planning and analysis, and treasury. Ms. Moses has provided strategic financial counsel on the company’s IPO and subsequent financings, spearheaded the implementation of financial controls and systems, and overseen the expansion of the Finance department.
Previously, Ms. Moses was a partner at Rankin McKenzie, LLC, where she served as acting chief financial officer and controller for venture-backed companies. In addition to preparing clients for growth by developing long-term financial plans and implementing financial systems, reporting and analysis, she led multiple clients through private placement offerings and acquisitions. Before joining Rankin McKenzie, Ms. Moses held roles of increasing responsibility at Deloitte, including providing tax services to clients and later focusing on strategic planning and internal communications in the Office of the CEO of Deloitte Tax.
Ms. Moses received her B.S. in Accounting from The Pennsylvania State University and is a certified public accountant in the State of North Carolina.
-
Jonathan Violin has deep experience aligning clinical and scientific evidence with strategies to efficiently finance discovery and development of novel therapeutics. He was the co-founder of privately-held Viridian Therapeutics and led the firm’s operations prior to its acquisition by miRagen Therapeutics (now Viridian Therapeutics, Inc., Nasdaq: VRDN). He previously served as founding CEO of two virtual drug discovery companies, Quellis Biosciences and Dianthus Therapeutics. Prior to that, Jonathan co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. Jonathan holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.